Guérette B, Asselin I, Vilquin J T, Roy R, Tremblay J P
Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, Canada.
Muscle Nerve. 1995 Jan;18(1):39-51. doi: 10.1002/mus.880180107.
Human and mouse (C57BL/10SnJ+/+) myoblasts were injected separately in the muscles of C57BL/10ScSn mdx/mdx mice. Mouse myoblasts (C57BL/10SnJ+/+) were also injected in normal mice (C57BL/10SnJ+/+ and BALB/c+/+). Some muscles that received a xenotransplantation (i.e., human myoblasts) were previously injected with a myotoxin, i.e., notexin. This treatment was not used for the allografts (i.e., mouse myoblasts). Human myoblast injections did not increase the number of dystrophin-positive cells above the background level due to backmutation. Moreover, the human myoblasts detected with an anti-HLA antibody decreased rapidly during the 6-week follow-up. The injection of normal mouse myoblasts in mdx mice did, however, increase the number of dystrophin-positive fibers. Moreover, numerous cells expressing mouse MHC class II, macrophages, granulocytes, neutrophils, natural killer cells, and a subset of T lymphocytes were detected by immunohistochemistry in cryostat sections of myoblast-injected muscles. These cells were present within 1 week of the myoblast injection in the muscle regions containing injected human or mouse myoblasts, and progressively decreased during the 6-week follow-up in the human myoblast transplantation. Lymphocyte infiltration reached a significant level following xeno- and alloincompatible transplantations. Antibodies against the human myoblasts and against alloincompatible myoblasts were also detected in the serum of the recipients. These results suggest that humoral and cellular immune reactions are responsible for the poor outcome of myoblast transplantation in mice and could be involved in failure of transplantation in Duchenne muscular dystrophy patients. These results indicate that adequate immunosuppression must be used in these patients.
将人类和小鼠(C57BL/10SnJ+/+)成肌细胞分别注射到C57BL/10ScSn mdx/mdx小鼠的肌肉中。小鼠成肌细胞(C57BL/10SnJ+/+)也被注射到正常小鼠(C57BL/10SnJ+/+和BALB/c+/+)体内。一些接受异种移植(即人类成肌细胞)的肌肉预先注射了一种肌毒素,即诺维毒素。同种异体移植(即小鼠成肌细胞)未采用这种处理方法。由于回复突变,人类成肌细胞注射并未使抗肌萎缩蛋白阳性细胞数量增加到背景水平以上。此外,在6周的随访期间,用抗HLA抗体检测到的人类成肌细胞迅速减少。然而,在mdx小鼠中注射正常小鼠成肌细胞确实增加了抗肌萎缩蛋白阳性纤维的数量。此外,通过免疫组织化学在注射成肌细胞的肌肉的低温切片中检测到大量表达小鼠MHC II类分子的细胞、巨噬细胞、粒细胞、中性粒细胞、自然杀伤细胞和一部分T淋巴细胞。这些细胞在含有注射的人类或小鼠成肌细胞的肌肉区域中,在成肌细胞注射后1周内出现,并在人类成肌细胞移植的6周随访期间逐渐减少。在异种和同种异体不相容移植后,淋巴细胞浸润达到显著水平。在受体血清中也检测到了针对人类成肌细胞和同种异体不相容成肌细胞的抗体。这些结果表明,体液免疫和细胞免疫反应是小鼠成肌细胞移植效果不佳的原因,并且可能与杜兴氏肌营养不良患者移植失败有关。这些结果表明,这些患者必须采用适当的免疫抑制措施。